How Central Review Complements Onsite Visits in Clinical Trials

Understanding the Shift to Hybrid Monitoring

Traditional onsite monitoring, once considered the gold standard for ensuring data integrity and patient safety in clinical trials, is now evolving into a hybrid approach. Centralized review plays a key role in this transformation under Risk-Based Monitoring (RBM) frameworks as per ICH E6(R2) guidelines.

Central monitoring allows sponsors to analyze large datasets remotely to detect anomalies, trends, and potential protocol violations. This analytical insight enhances the quality and efficiency of onsite monitoring, enabling Clinical Research Associates (CRAs) to focus on high-risk areas rather than performing 100% Source Data Verification (SDV).

This synergy ensures better resource allocation, quicker issue resolution, and improved compliance—all while reducing costs and burden on site staff.

How Central Review Informs Onsite Visit Planning

One of the major advantages of centralized monitoring is its role in prioritizing and focusing onsite visits. Centralized teams can identify trends or flags based on the following parameters:

• High number of unresolved queries
• Delayed or missing AE/SAE reports
• Protocol deviations (e.g., out-of-window visits)
• Incomplete informed consent documentation
• Unusual subject enrollment or discontinuation patterns

These findings guide CRAs to concentrate their efforts on problem areas. For example, if Site A has an above-threshold protocol deviation rate (>4%) or a high volume of overdue queries (n=75+), the next onsite visit would emphasize those metrics.

Thus, central review enables data-driven, targeted monitoring—a key tenet of RBM implementation.

Case Study: Optimizing CRA Visit Based on Central Findings

In a global vaccine trial, central monitors observed consistent discrepancies in visit dates at Site 008. The CRA was notified to prioritize verifying source documents related to visit scheduling and subject dosing. During the onsite visit, the CRA discovered that the site coordinator had misunderstood the visit window algorithm in the EDC. This led to a corrective training and update in site SOP.

This real-time feedback loop—between central review and CRA actions—enhanced protocol adherence and prevented a larger compliance issue. You can learn more about these SOPs at PharmaSOP: Hybrid Monitoring SOP Templates.

Enhancing CRA Efficiency Through Centralized Insights

Onsite monitors often face time constraints and administrative overload. Central review alleviates this by pre-screening data and generating visit agendas. Examples include:

• Pre-visit reports highlighting open issues
• Summary of delayed AE/SAE entries per subject
• Subject dropout reasons by site
• Query aging reports (e.g., queries open >15 days)

These insights allow CRAs to arrive at the site with a prioritized checklist, saving hours of document navigation. It also enables focused discussions with site staff and better oversight documentation in the Trial Master File (TMF).

Data-Driven Triggers for Remote and Onsite Escalation

Central review is critical in initiating timely escalations and prompting onsite action. Some examples include:

• SAE Reporting Delays: If the time from event onset to EDC entry exceeds 5 days
• Data Fabrication Suspicion: Repeated identical vital signs or lab values
• High Subject Withdrawal Rate: >20% dropouts at a single site
• Incomplete ICF Uploads: Missing signed consent in EDC or eTMF

Each of these triggers may warrant immediate site contact, targeted CRA visit, or Quality Assurance (QA) audit. The documentation of signal review and escalation steps must be captured in a centralized RBM log or risk signal tracker.

Tools Enabling Central and Onsite Integration

Modern clinical platforms allow seamless collaboration between centralized reviewers and CRAs. Tools include:

• EDC with built-in RBM dashboards (e.g., Medidata Rave, Oracle Clinical One)
• Site dashboards in CTMS that track protocol deviations, enrollment, and SDV progress
• JIRA or ticketing tools to assign findings to CRAs for resolution
• Audit Trail and eTMF integration to archive actions and confirmations

Visit the resources section at PharmaValidation: Centralized Monitoring Compliance Tools for validated templates and tracker examples.

Regulatory Support for Hybrid Monitoring Models

Both FDA and EMA support hybrid monitoring approaches under RBM, encouraging central oversight complemented by strategic onsite visits. ICH E6(R2) explicitly recommends a mix of centralized and on-site activities based on risk assessments. Inspectors will often look for:

• Documented rationale for site selection and visit frequency
• Linkage between central findings and site action plans
• Evidence of communication between central monitors and CRAs
• Archived risk signals and resulting follow-up logs

Proper documentation ensures inspection readiness and alignment with global GCP expectations.

Challenges in Hybrid Monitoring Implementation

Despite its benefits, integrating central review with onsite monitoring poses challenges:

• Delayed Data Entry: Central review is only as good as the timeliness of EDC updates
• Communication Gaps: Misalignment between central teams and field CRAs
• Lack of SOPs: Hybrid processes often lack formal documentation
• Tool Fragmentation: Using multiple, disconnected systems hinders visibility

To mitigate this, sponsors should establish centralized escalation SOPs, communication protocols, and system integration plans.

Conclusion

Centralized review does not replace onsite monitoring—it strengthens it. By providing real-time, data-driven insights, it allows CRAs to target risk areas, optimize their visits, and contribute to better compliance, safety, and quality. The hybrid model is now a regulatory-endorsed standard, and sponsors must invest in the right tools, training, and SOPs to operationalize this synergy effectively.

Further Reading

• FDA Guidance on Risk-Based Monitoring
• ICH E6(R2) Guidelines

Understanding Centralized Monitoring in Risk-Based Monitoring

What Is Centralized Monitoring in RBM?

Centralized monitoring is a core component of Risk-Based Monitoring (RBM), enabling sponsors and CROs to detect data anomalies and site performance issues without on-site visits. Defined by ICH E6(R2), centralized monitoring involves the remote evaluation of accumulating data using statistical, analytical, and visual tools. The goal is early detection of risks affecting patient safety and data quality.

Unlike traditional Source Data Verification (SDV), centralized monitoring relies on aggregate and individual data points, captured from eCRFs, EDC systems, or lab databases. It enhances trial oversight by allowing proactive intervention before issues escalate.

Core Components of Centralized Monitoring

Effective centralized monitoring systems include the following key elements:

• Key Risk Indicators (KRIs): Metrics such as AE reporting rates, query resolution times, and visit compliance
• Statistical Algorithms: Outlier detection, variability assessments, and trend analysis
• Dashboards and Visualizations: Interactive data tools to identify and drill down into anomalies
• Data Review Logs: Audit trails of observations, escalations, and resolutions
• Communication Plan: Defined path for escalating findings to CRAs or study teams

These tools help sponsors detect hidden patterns across sites that may not be visible during periodic on-site monitoring.

Workflow of Centralized Monitoring in a Clinical Trial

Here is a typical centralized monitoring process:

1. Data Extraction: Raw data from EDC, lab systems, and CTMS is integrated
2. Baseline Metrics: Establish reference values for comparison (e.g., AE rate = 1.5/patient)
3. Signal Detection: Algorithms flag deviations from baseline across sites or patients
4. Review and Escalation: Central monitor evaluates signals and escalates to site CRA
5. Mitigation and Documentation: Action plans are created and documented in the TMF

This cycle repeats weekly or bi-weekly depending on trial risk level.

Benefits of Centralized Monitoring

Centralized monitoring provides numerous advantages over traditional on-site models:

• Reduces the need for frequent site visits
• Enables faster detection of data issues and protocol deviations
• Improves data quality and decision-making
• Supports regulatory compliance with ICH E6(R2)
• Enables prioritization of high-risk sites for targeted oversight

One sponsor implementing centralized RBM reported a 35% decrease in monitoring costs and a 60% faster deviation detection time.

Real-World Example: Central Monitoring Triggering Action

In a global Phase III oncology trial, centralized monitoring flagged a spike in missing lab values at a particular site. Upon further investigation, it was found that the site had changed its lab vendor without notifying the sponsor. Centralized monitoring allowed the team to detect and correct this issue within 48 hours, avoiding potential GCP violations.

More centralized monitoring examples are available in EMA’s RBM publications: EMA website.

Key Risk Indicators (KRIs) in Centralized Monitoring

KRIs are the backbone of centralized monitoring, offering predefined metrics to detect risks. Commonly used KRIs include:

• Query Resolution Time: Indicates data entry quality and site responsiveness
• AE/SAE Reporting Ratio: Flags underreporting or overreporting patterns
• Visit Window Deviations: Assesses protocol adherence
• CRF Completion Rates: Measures site performance in timely data entry
• ePRO Completion Compliance: Tracks patient-reported outcomes

KRIs are often visualized on dashboards. When thresholds are breached, alerts are triggered for review and action.

Challenges in Centralized Monitoring Implementation

Despite its advantages, implementing centralized monitoring presents challenges such as:

• Data Integration: Consolidating EDC, lab, and CTMS data in near real-time
• System Compatibility: Harmonizing across legacy platforms
• Training Requirements: Central monitors require statistical and GCP understanding
• Over-Reliance on Algorithms: Risk of missing human context without CRA collaboration

Organizations should adopt centralized monitoring SOPs and maintain cross-functional collaboration to overcome these barriers. Templates are available at PharmaSOP.

Tools and Technologies Enabling Centralized Monitoring

Today’s centralized monitoring is driven by advanced technologies:

• EDC with Real-Time Dashboards
• Statistical Review Engines (e.g., SAS-based)
• Clinical Analytics Platforms with predictive modeling
• Data Lakes and Integrators to merge lab, imaging, and CTMS data
• Risk Management Portals for cross-team collaboration

Some sponsors integrate centralized monitoring into their CTMS and eTMF systems for seamless documentation and regulatory audit trails.

Regulatory Expectations and Compliance

Regulatory bodies like FDA and EMA endorse centralized monitoring as part of modern GCP. The FDA’s RBM guidance states:

“Centralized monitoring activities should be documented and traceable, with pre-defined triggers and resolution workflows.”

All centralized monitoring decisions, risk signals, and corrective actions must be documented in the TMF. This ensures audit readiness and supports a robust Quality Management System (QMS).

Explore FDA RBM guidance at FDA.gov.

Conclusion

Centralized monitoring is transforming how clinical trials are managed, allowing teams to focus resources on areas of true risk. Through advanced analytics, real-time data evaluation, and integration with RBM, centralized monitoring supports better oversight, higher data quality, and regulatory compliance. As trials become more complex, centralized monitoring will play a key role in efficient and effective study conduct.

Further Resources:

• PharmaValidation: Centralized Monitoring SOPs and Tools
• ICH E6(R2) GCP Guidelines